Addition of Ivabradine to β-Blocker Improves Exercise Capacity in Systolic Heart Failure Patients in a Prospective, Open-Label Study

Advances in Therapy

Volumn 32, Issue 2, 2015, Pages 108-119

  Bagriy, A E ^a   Schukina, E V ^a   Samoilova, O V ^a   Pricolota, O A ^a   Malovichko, S I ^a   Pricolota, A V ^a   Bagriy, E A ^a  

^a DONETSK NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Carvedilol; Heart failure; Heart rate; Ivabradine; blockers

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR INHIBITOR; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; WARFARIN; BENZAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARDIOVASCULAR AGENT; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; DRUG DOSE TITRATION; EXERCISE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RESTING HEART RATE; SINUS RHYTHM; SYSTOLIC HEART FAILURE; AGED; COMBINATION DRUG THERAPY; EXERCISE TOLERANCE; HEART FAILURE, SYSTOLIC; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AGED; BENZAZEPINES; CARBAZOLES; CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; EXERCISE; EXERCISE TOLERANCE; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84925485323     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0185-5     Document Type: Article

References (25)

1. Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12(10):1076–84.
2. Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119(4):515–23.
3. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464–74.
4. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 2009;30(4):478–86.
5. Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13(6):670–80.
6. Franke J, Wolter JS, Meme L, et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol. 2013;102(1):23–31.
7. Russell SJ, Oliver M, Edmunds L, et al. Optimized beta-blocker therapy in heart failure: is there space for additional heart rate control? Br J Cardiol. 2012;19:21–3.
8. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886–94.
9. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406.
10. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet. 2010;376(9744):875–85.
11. Savelieva I, Camm AJ. I(f) inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31(2):95–107.
12. Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61(2):127–37.
13. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109(13):1674–9.
14. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10:550–5.
15. Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218–24.
16. Reil JC, Tardif JC, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62(21):1977–85.
17. Ambrosy AP, Vaduganathan M, Mentz RJ, et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013;165(2):216–25.
18. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107(8):1208–14.
19. Meredith PA, Ostergren J, Anand I, et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol. 2008;52(24):2000–7.
20. Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009;95(1):56–62.
21. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284(2):H676–82.
22. Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002;282(2):H672–9.
23. Steg P, Lopez-de-Sa E, Schiele F, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care. 2013;2(3):270–9.
24. Amosova E, Andrejev E, Zaderey I, et al. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25(6):531–7.
25. Zugck C, Martinka P, Stoeckl G, et al. Heart rate control in chronic systolic heart failure patients in Germany: results of a nationwide survey. Eur Heart J. 2013;34(suppl 1)P646.